Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Verbascoside (Acteoside; Kusaginin; TJC-160), a natural product isolated from Lantana camara, is novel and potent inhibitor of the Oligomerization of Pneumolysin. It acts as an ATP-competitive inhibitor of PKC, with an IC50 of 25 µM, with antitumor, anti-inflammatory and antineuropathic pain activity.
ln Vitro |
Verbascoside has an IC50 of 25 μM and is an ATP competitive PKC inhibitor. In terms of ATP and histones, verbascoside has a Kis of 22 and 28 μM, respectively. Verbascoside, with an IC50 of 13 μM, exhibits strong anti-tumor action against L-1210 cells[1]. Verbascoside (5, 10 μM) prevents T cell costimulators CD86 and CD54, pro-inflammatory cytokines, and NFκB pathways from being activated in THP-1 cells by 2,4-dinitrochlorobenzene (DNCB) [2].
|
---|---|
ln Vivo |
In a mouse model of 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD), verbascoside (1%) decreases the incidence of overall scratching behavior and the severity of skin lesions. In DNCB-induced skin damage, verbascoside also inhibits the expression of pro-inflammatory cytokines TNF-α, IL-6, and IL-4 mRNA [2]. Intraperitoneally administered verbascoside (50, 100 mg/kg) does not alleviate cold allodynia resulting from chronic compression injury (CCI). On day three, verbascoside (200 mg/kg, intraperitoneally) decreased the rats' hypersensitivity to cold-stimulated acetone. Verbascoside also considerably lessened the behavioral alterations linked to neuropathy. Verbascoside also raises Bcl-2 and decreases Bax on day three [3].
|
References |
[1]. Herbert JM, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C. J Nat Prod. 1991 Nov-Dec;54(6):1595-600.
[2]. Li Y, et al. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. Int Arch Allergy Immunol. 2018;175(4):220-230. [3]. Amin B, et al. The Effect of Verbascoside in Neuropathic Pain Induced by Chronic Constriction Injury in Rats. Phytother Res. 2016 Jan;30(1):128-35 |
Molecular Formula |
C29H36O15
|
---|---|
Molecular Weight |
624.5872
|
CAS # |
61276-17-3
|
SMILES |
O=C(O[C@@H]1[C@@H](CO)O[C@@H](OCCC2=CC=C(O)C(O)=C2)[C@H](O)[C@H]1O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)/C=C/C4=CC=C(O)C(O)=C4
|
InChi Key |
FBSKJMQYURKNSU-ZLSOWSIRSA-N
|
InChi Code |
InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
|
Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-Dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]
(E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
Synonyms |
Kusaginin TJC-160 TJC 160TJC160Acetoside Kusaginin
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~160.11 mM)
DMSO : ≥ 100 mg/mL (~160.11 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL | |
5 mM | 0.3202 mL | 1.6011 mL | 3.2021 mL | |
10 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.